阿普米司特治疗银屑病≥156周长期安全性汇总分析
该分析汇总ESTEEM 1和2两项3期随机对照试验中阿普米司特30mg每日两次治疗银屑病的安全性数据,覆盖1184例患者、1902.2患者年。结果显示0至≥156周内未出现新的不良事件,不良事件、严重不良事件及因不良事件停药未随长期暴露增加,长期安全性可接受且耐受性良好。
要点
- 0至≥156周未报告新的影响≥5%人群的不良事件
- 不良事件、严重不良事件及因不良事件停药未随长期暴露增加
- 主要心脏事件、恶性肿瘤、抑郁及自杀企图发生率未较0至≤52周升高
核心结论
- 阿普米司特在银屑病患者中显示可接受的安全性特征,≥156周一般耐受性良好。
研究设计与样本
- 汇总ESTEEM 1和2两项3期随机对照试验的安全性数据,阿普米司特暴露期0至≥156周,纳入1184例每日两次口服阿普米司特30mg的患者,共1902.2患者年。
主要发现
- 0至≤52周期间发生于≥5%患者的不良事件包括腹泻、恶心、上呼吸道感染、鼻咽炎、紧张性头痛和头痛。
- 0至≥156周未报告新的影响≥5%人群的不良事件,不良事件、严重不良事件及因不良事件停药未随长期暴露增加。
- 0至≥156周主要心脏事件EAIR 0.5/100患者年、恶性肿瘤EAIR 1.2/100患者年、抑郁EAIR 1.8/100患者年、自杀企图EAIR 0.1/100患者年,均未较0至≤52周升高。
- 未报告严重机会性感染、结核再激活或实验室指标的临床有意义影响。
临床怎么用
- 长期使用阿普米司特治疗银屑病时,可参考该汇总数据评估≥156周的总体安全性,关注腹泻、恶心、上呼吸道感染等常见不良事件。
局限性
- 研究脱落率较高,仅21%患者持续治疗>156周,但多数脱落与安全性问题无关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. OBJECTIVE: Assess long-term safety of oral apremilast in psoriasis patients. METHODS: Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2. RESULTS: The 0 to ≥156-week apremilast-exposure period included 1184 patients treated twice daily with apremilast 30 mg (1902.2 patient-years). During 0 to ≤52 weeks, the adverse events (AEs) that occurred in ≥5% of patients included diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache. From 0 to ≥156 weeks, no new AEs (affecting ≥5% of the population) were reported. AEs, serious AEs, and study drug discontinuations caused by AEs did not increase with long-term exposure. During the 0 to ≥156-week period, the rates of major cardiac events (exposure-adjusted incidence rate [EAIR] 0.5/100 patient-years), malignancies (EAIR 1.2/100 patient-years), depression (EAIR 1.8/100 patient-years), or suicide attempts (EAIR 0.1/100 patient-years) did not increase in comparison with the rates found during the 0 to ≤52-week period. No serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported. LIMITATIONS: This study had a high dropout rate (21% of patients ongoing >156 weeks); most were unrelated to safety concerns. CONCLUSIONS: Apremilast demonstrated an acceptable safety profile and was generally well tolerated for ≥156 weeks.
引用
- Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017. PMID: 28416342. doi:10.1016/j.jaad.2017.01.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。